



Times subject to small changes based on the final event production



***27th Annual Prostate Cancer Foundation
Scientific Retreat***

October 22 - 23, 2020



AGENDA

Thursday, October 22, 2020

*All times in U.S. PDT

VIRTUAL POSTER SESSION

Starting on Tuesday October 20, 2020, 12:01 AM U.S. PDT

GENERAL SESSIONS

Welcome and Opening Remarks

7:00 AM - 7:05 AM

Howard Soule, PhD
Prostate Cancer Foundation

Session 1: Prostate Cancer, Androgens and COVID-19

7:05 AM - 8:05 AM

Moderator: Nima Sharifi, MD
Cleveland Clinic

Introduction

Nima Sharifi, MD
Cleveland Clinic

Regulation and Targeting of SARS-CoV-2 Entry Factors ACE2 and TMPRSS2 in Human Airway Epithelial Cell Subtypes

Arul Chinnaiyan, MD, PhD
University of Michigan; Michigan Center for Translational Pathology

Randomized Clinical Trial of Camostat vs. Placebo in COVID-19 Outpatients


Joseph Vinetz, MD
Yale University

Hormonal Intervention for the Treatment of Veterans with COVID-19 Requiring Hospitalization (HITCH)

Matthew Rettig, MD
University of California, Los Angeles; VA Greater Los Angeles Healthcare System

Live Session Discussion

Thursday, October 22, 2020



8:05 AM - 8:10 AM Please Return to the Virtual Lobby to Join the Next Session

Session 2: Circulating DNA Methylation Biomarkers for Diagnosis, Prognosis and Treatment Selection

8:10 AM - 9:10 AM

Moderator: Gerhardt Attard, MD, PhD
University College London Cancer Institute, UK

Introduction

Gerhardt Attard, MD, PhD
University College London Cancer Institute, UK

Using 5-hydroxymethylcytosine Sequencing to Interrogate Biological Drivers of Advanced Prostate Cancer

Martin Sjöström, MD, PhD
University of California, San Francisco

Opportunities for Tracking the Prostate Cancer Methylome in Plasma

Gerhardt Attard, MD, PhD
University College London Cancer Institute, UK


Circulating Methylation Biomarkers for Neuroendocrine Prostate Cancer Differentiation

Francesca Demichelis, PhD
University of Trento, Italy

Live Session Discussion

9:10 AM - 9:15 AM Please Return to the Virtual Lobby to Join the Next Session

Thursday, October 22, 2020



SPECIAL LECTURE

9:15 AM - 9:38 AM

***Dual Functions of SPOP and ERG Dictate
Androgen Therapy Responses in Prostate Cancer***

Jean-Philippe Theurillat, MD

Institute of Oncology Research, Switzerland

*Introduced by Prof. Mark Rubin, MD
University of Bern, Switzerland*

Live Discussion

SPECIAL LECTURE

9:38 AM - 9:53 AM


***A Community Resource of Genetically-Engineered Mouse Models that Recapitulate the
Phenotypic Spectrum of Prostate Cancer***

Cory Abate-Shen, PhD

Columbia University Irving Medical Center

Live Discussion

Thursday, October 22, 2020



SPECIAL LECTURE
9:53 AM - 10:15 AM

The Genomic Evolution of Prostate Cancer

Paul Boutros, PhD, MBA
University of California, Los Angeles

Introduced by Howard Soule, PhD
Prostate Cancer Foundation

Live Discussion

10:15 AM - 10:45 AM BREAK


Please Return to the Virtual Lobby to Join the Next Session

KEYNOTE ADDRESS
10:45 AM - 11:50 AM

Michael Milken
Founder and Chairman
Prostate Cancer Foundation

Introduced by Stuart Holden, MD
Prostate Cancer Foundation

11:50 AM - 11:55 AM Please Return to the Virtual Lobby to Join the Next Session



Thursday, October 22, 2020

DEBATE:

Prostate Cancer Genomic Classifiers; Are We Ready for Prime Time?

11:55 AM - 12:40 PM

Moderators:

Felix Feng, MD (University of California, San Francisco)

Rana McKay, MD (University of California, San Diego)

Speakers:

Pro: Daniel Spratt, MD (University of Michigan)

Con: Daniel Lin, MD (University of Washington)

Live Discussion

12:40 PM - 12:45 PM Please Return to the Virtual Lobby to Join the Next Session

Session 3: Targeting MYC, the Emperor of Oncoproteins

12:45 PM - 2:00 PM

Moderator: Sarki Abdulkadir, MD, PhD

Northwestern University

Introduction

Sarki Abdulkadir, MD, PhD

Northwestern University

MYC and the Tumor Immune Microenvironment

Dean Felsher, MD, PhD


Stanford University

Advances in MYC Therapeutic Targeting in Cancer

Rosalie Sears, PhD

Oregon Health & Science University

Thursday, October 22, 2020



N-Myc as a Driver of Lineage Plasticity in Advanced Prostate Cancer

David Rickman, PhD

Weill Cornell Medicine

Small-Molecule MYC Inhibitors

Sarki Abdulkadir, MD, PhD

Northwestern University

Live Session Discussion

2:00 PM - 2:05 PM **Please Return to the Virtual Lobby to Join the Next Session**

SPECIAL LECTURE

2:05 PM - 2:35 PM

Current Challenges in Treatment of Patients with Metastatic Prostate Cancer

Himisha Beltran, MD

Harvard: Dana Farber Cancer Institute

Introduced by Rana McKay, MD

University of California, San Diego

Live Discussion

PCF Press:


Highlights from Day 1 and Look Forward at Day 2

2:35 PM - 2:45 PM

Karen Knudsen, PhD

Thomas Jefferson University

END DAY ONE



Friday, October 23, 2020

PANEL DISCUSSION:

Prostate Cancer Disparities: Lessons from the COVID-19 Era

7:00 AM – 8:00 AM

Moderator: Brandon Mahal, MD
University of Miami

Panelists:

Erin Kobetz, PhD, MPH (University of Miami)
Monica Baskin, PhD (University of Alabama at Birmingham)
Thomas Farrington (Prostate Health Education Network)
Randy Vince Jr., MD (University of Michigan)

Introduced by Howard Soule, PhD
Prostate Cancer Foundation

Live Discussion

8:00 AM - 8:05 AM ***Please Return to the Virtual Lobby to Join the Next Session***


Session 4: Late Breaking Clinical Data for Prostate Cancer Patients

8:05 AM - 9:20 AM

Moderators: Howard Soule, PhD
Prostate Cancer Foundation

Introduction

Howard Soule, PhD
Prostate Cancer Foundation



Friday, October 23, 2020

Combinatorial Targeting of AR and AKT with Abiraterone and Ipatasertib for mCRPC with and without PTEN loss: The Ipatential150 Phase 3 Trial

Johann de Bono, MD, PhD

The Institute of Cancer Research; Royal Marsden Hospital, London, UK

Phase 1 Clinical Profile of AMG 160, a Half-Life Extended PSMA Bispecific T-cell Engager (BiTE®) Immunotherapy for Patients with Metastatic Castration-Resistant Prostate Cancer

Matthew Rettig, MD

University of California, Los Angeles; VA Greater Los Angeles Healthcare System

Phase 1 Study of AMG 509, a STEAP1 x CD3 T Cell-Recruiting XmAb® 2+1 Immune Therapy, in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Wm. Kevin Kelly, DO

Sidney Kimmel Medical College at Thomas Jefferson University; Sidney Kimmel Cancer Center

Human Costimulatory Bispecific Antibodies in Cancer Immunotherapy: Focus in Prostate Cancer

Dimitris Skokos, PhD

Regeneron Pharmaceuticals


Elizabeth Miller, MD

Regeneron Pharmaceuticals

Live Session Discussion

9:20 AM - 9:25 AM Please Return to the Virtual Lobby to Join the Next Session

Friday, October 23, 2020



Session 5: Microbiome and Cancer

9:25 AM - 10:25 AM

Moderator: Ellen Filvaroff, PhD
Bristol Myers Squibb

Introduction

Ellen Filvaroff, PhD
Bristol Myers Squibb

The Plasticity of the Microbiome in Colorectal Cancer

Christian Jobin, PhD
University of Florida

Host-Microbiome Interactions in Human Cancer

Ran Blekhman, PhD
University of Minnesota

Gut Microbiota and Cancer Immunotherapy


Andrew Y. Koh, MD
University of Texas Southwestern Medical Center

Live Session Discussion

10:25 AM - 10:55 AM BREAK

Please Return to the Virtual Lobby to Join the Next Session

Friday, October 23, 2020



SPECIAL LECTURE

10:55 AM - 11:30 AM

State of the Science 2020

Jonathan W. Simons, MD

Prostate Cancer Foundation

Introduced by Howard Soule, PhD

Prostate Cancer Foundation

11:30 AM - 11:35 AM Please Return to the Virtual Lobby to Join the Next Session

SPECIAL LECTURE

11:35 AM - 11:50 AM


VA-PCF Collaboration: Streamlined Genetic Sequencing in Veterans for Improved Clinical Care and Research Opportunities

Julie Graff, MD

VA Portland Health Care System

Introduced by Rebecca Levine

Prostate Cancer Foundation



Friday, October 23, 2020

SPECIAL LECTURE

11:50 AM - 12:15 PM

A Polygenic Risk Score for Predicting Prostate Cancer in Men of African Descent

Christopher Haiman, ScD

Center for Genetic Epidemiology and Norris Comprehensive Cancer Center,
University of Southern California

*Introduced by Howard Soule, PhD
Prostate Cancer Foundation*

Live Discussion

12:15 PM - 12:20 PM Please Return to the Virtual Lobby to Join the Next Session

Session 6: Advances for Immunotherapy in Prostate Cancer

12:20 PM - 1:15 PM

Moderator: Howard Soule, PhD
Prostate Cancer Foundation

Introduction


Howard Soule, PhD
Prostate Cancer Foundation

Clinical Development of PSCA-Targeted CAR T Cells for Advanced Prostate Cancer

Tanya Dorff, MD
City of Hope

Co-expression of a Novel TGF β R Dominant Negative Receptor to Enhance PSMA Chimeric Antigen Receptor Therapy in the Treatment of Castrate Resistant Prostate Cancer Patients

Naomi Haas, MD
University of Pennsylvania



Friday, October 23, 2020

Development of a First-in-Class Shared Neo-Antigen Vaccine for the Treatment of Prostate Cancer

M. Alejandro Sepulveda, PhD
Janssen Research & Development, LLC

Live Discussion

1:15 PM - 1:20 PM Please Return to the Virtual Lobby to Join the Next Session

Session 7: Recent Advances in Antibody-Drug Conjugates for the Treatment of Cancer
1:20 PM - 2:30 PM

Moderator: Marco Gottardis, PhD
Janssen Research & Development, LLC

Introduction

Marco Gottardis, PhD
Janssen Research & Development, LLC

Antibody Drug Conjugates: From Early Stage Research to Clinically Approved Drugs

Peter Senter, PhD
Seattle Genetics

Novel Approaches to Development of Antibody-Drug Conjugates for the Treatment of Cancer

Yuuri Hashimoto, PhD
Daichi Sankyo Co., Ltd.

PSMA Antibody Targeted Amanitin Conjugate (PSMA-ATAC): Introducing a Novel Mode of Action into Prostate Cancer Therapy

George Badescu, PhD
Heidelberg Pharma AG

Live Session Discussion



Friday, October 23, 2020

Closing Remarks

2:30 PM - 2:35 PM


Howard Soule, PhD

Prostate Cancer Foundation

Jonathan W. Simons, MD

Prostate Cancer Foundation

**END DAY TWO
MEETING ADJOURNED**



Program Committee:

Program Committee Co-Chair: Howard Soule, PhD (Prostate Cancer Foundation)

Program Committee Co-Chair: Andrea Miyahira, PhD (Prostate Cancer Foundation)

Jonathan W. Simons, MD (Prostate Cancer Foundation)

Sarki Abdulkadir, MD, PhD (Northwestern University)

Gerhardt Attard, MD, PhD (University College London Cancer Institute)

Felix Feng, MD (University of California, San Francisco)

Ellen Filvaroff, PhD (Bristol Myers Squibb)

Marco Gottardis, PhD (Janssen Pharmaceuticals)

Brandon Mahal, MD (University of Miami)

Times subject to small changes based on the final event production

We deeply thank our Retreat supporters for providing funding for this educational initiative.

SANOFI GENZYME 

janssen  Oncology

PHARMACEUTICAL COMPANIES OF *Johnson & Johnson*



AMGEN®



 Bristol Myers Squibb™

CLOVIS ONCOLOGY 

 Daiichi-Sankyo

 Pfizer Oncology

 astellas

AstraZeneca 

 FOUNDATION MEDICINE®

Genentech
A Member of the Roche Group

Constellation 
PHARMACEUTICALS

Dendreon® 

ESSA

 MERCK
INVENTING FOR LIFE